By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Imaging agents are chemicals or substances used in medical imaging operations to improve the visibility of particular human organs, tissues, or structures. They are given to patients either before or during imaging tests like X-rays, CT scans, MRIs, PET scans, and ultrasounds.
Imaging agents’ main goal is to increase the contrast between various tissues or to draw attention to particular physiological processes, which helps doctors diagnose and assess patients’ diseases.
Imaging agents function by interacting with bodily tissues and generating signals that imaging equipment can pick up. Various imaging modalities employ various sorts of imaging agents:
PET scans use radioactive tracers, typically marked with positron-emitting isotopes, to visualize physiological and metabolic processes occurring within the body. These tracers are frequently employed to evaluate cellular activity and identify diseases like cancer.
Medical personnel rely heavily on imaging agents to give them important diagnostic data. They support abnormality detection, illness progression assessment, therapy response monitoring, and surgical intervention guidance.
However, before undertaking any imaging treatment employing contrast agents, it is important to carefully assess and address any risks, such as allergic responses or unpleasant effects, that may be associated with the use of imaging agents.
The Global Imaging Agents Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The FDA has approved a radio hybrid imaging agent to locate and assess the extent of prostate cancer. According to a news statement from Blue Earth Diagnostics, the FDA has approved flotufolastat F 18, a positron emission tomography (PET) imaging agent for lesions that are positive for the prostate-specific membrane antigen (PSMA) in men with prostate cancer.
This is the first and only PSMA-targeted drug approved by the FDA that uses radiohybrid (rh) technology. To aid medical professionals in the identification and localization of prostate cancer, flotufolastat F 18 was created. It represents a novel class of high-affinity, purpose-engineered radiopharmaceuticals that target PSMA and are based on revolutionary [rh] technology.
These radiopharmaceuticals may be used for therapeutic and diagnostic purposes. Men who are eligible for initial definitive therapy and have probable metastases can use this indication.
